SEC
SlamSEC
SearchBrowseEarnings

HERON THERAPEUTICS, INC. /DE/

Nasdaq:HRTX
Pharmaceutical Preparations·SAN DIEGO, CA
OverviewAll FilingsSum FinCreditInsidersGovernance
OverviewAll FilingsSum FinCreditInsidersGovernance

Summary Financials

Herons are long-legged, long-necked, freshwater and coastal birds in the family Ardeidae, with 75 recognised species, some of which are referred to as egrets or bitterns rather than herons. Members of the genus Botaurus are referred to as bitterns, and, together with the zigzag heron, or zigzag bittern, in the monotypic genus Zebrilus, form a monophyletic group within the Ardeidae.

Revenue
$127.0M
+18.0% YoY
FY 2025
Adj. EBITDA
-$107.7M
-84.8% margin
FY 2025
Net Income
-$110.6M
-87.0% margin
FY 2025
EPS (Diluted)
-$0.80
FY 2025
Stock Price
$0.86
-2.9%
2026-03-17
52W Range
$0.88 – $2.61
P/E Ratio
-1.1x
Market Cap
$161.4M
Cash
$25.8M
FY 2025
Total Debt
—
Net Cash
$25.8M
FY 2025
Enterprise Value
$135.6M
Debt / EBITDA
0.2x
FY 2025
EV / EBITDA
-1.3x
Employees
—